您好,欢迎来到佐思信息
全国服务热线:
400-009-0050
佐思信息专注支持企业决策
您当前的位置:首页>>研究报告>>物流

2016-2026年全球药物运输技术市场研究报告
Drug Delivery Technologies Market Forecast 2016-2026

2016-2026年全球药物运输技术市场研究报告
【报告编号】:No.25975
【发布时间】:2016-07
【关 键 字】:Drug Delivery    药物运输   
【报告页数】:214页
【报告价格】:电子版:2639美元
【交付方式】:Email发送或EMS快递
【订购热线】:


400-009-0050(全国24小时服务)
北京:010-82863481
上海:021-64871266 021-64872612

报告目录下载订购协议下载在线咨询

    专业、专注于为企业提供真正有价值的全球市场调查信息,是我们的使命。我们是中国第一家汇集全球众多行业研究机构研究成果的平台,致力于为企业决策提供最有效的市场资讯,特别是为中国企业了解和进入国际市场迈出第一步,提供全面的信息参考,我们跨越语言及时间的障碍,在信息爆炸的当下,努力为客户提供最有价值的全球产业资讯。我们公司也拥有独立的研究机构,聚焦于中国市场的研究,为国内外企业在中国市场大展宏图提供市场研究支持。

• 我们在全球的合作伙伴>>• 我们的研究中心>>

  • 英文摘要
  • 中文摘要
  • 索取简版报告
  • 物流行业的相关报告
DESCRIPTION
 
What can be expected from the Drug Delivery Technologies Market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects.
 
Our 214-page report provides 137 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across all the major regional and national drug delivery technologies market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.
 
Forecasts from 2016-2026 and other analyses show you commercial prospects
 
Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT analysis) and commercial developments.
 
See revenue forecasts for the leading regional and national markets
 
How will leading national and regional markets perform to 2026? Our study forecasts revenues in national markets, including:
 
US
EU5 (Germany, France, UK, Spain and Italy)
Japan
China
India
Brazil
Russia
South Korea
Mexico
Rest of the World
 
Leading companies and potential for market growth
 
Visiongain forecasts overall revenue for the Drug Delivery Technologies Market will reach $259.1bn in 2020. We predict high revenue growth over the forecast period driven by big pharma seeking diversification of their top-selling products and a growing demand for more patient-friendly treatments in healthcare.
 
Our work analyses the key companies in the market. See visiongain's analysis of ten leading companies, including:
 
Alkermes
3M
Skyepharma
Becton Dickinson and Company (BD)
Antares Pharma
pSivida
Applied Pharma Research (APR)
Ethypharm
Glycologic
NanoPass Technologies
 
 
A company profile gives you the following information where available:
 
Discussion of a company's activities and outlook including regional and national revenue shares
Historic revenue, analysis and discussion of company performance
Analysis of major products/services currently available on the market
Acquisitions and strategic partnerships
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
 
What issues will affect the drug delivery technologies industry?
 
Our new report discusses issues and events affecting the drug delivery technologies market. You will find discussions, including qualitative analyses:
 
Highly fragmented and competitive market with significant variations in different geographic regions
Changing political and regulatory landscape changing the prospects of future products and reimbursement opportunities
Future opportunities for drug delivery technologies
You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.
 
How the Drug Delivery Technologies Market Forecast 2016-2026: Analysis of Oral, Inhalable, Injectable/Implantable, Transdermal, Ocular and Nasal/Buccal Drug Delivery Technologies; Forecasts for Biologics, Vaccines and Major National Markets and Assessment of Leading Drug Delivery Companies including 3M, BD and Alkermes report helps you:
 
In summary, our 214-page report gives you the following knowledge:
 
Revenue forecasts to 2026 for the Drug Delivery Technologies market - discover the industry's prospects, finding promising places for investments and revenues
Revenue forecasts to 2026 for three major regional markets - US, EU5 and Rest of the World
Revenue forecasts to 2026 for the leading national markets - US, Germany, France, UK, Spain, Italy, Japan, China, India, Brazil, Russia, South Korea, Mexico and Rest of the World
Assessment of leading companies - analysis of services, business operations, revenue (where available) and mergers & acquisitions
Discussion of what stimulates and restrains companies and the market
Prospects for established firms and those seeking to enter the market
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.
 
Information found nowhere else
 
With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
 
Visiongain's study is for everybody needing commercial analyses for the drug delivery technologies market and leading companies. You will find data, trends and predictions. Please order our report now.
 
visiongain is a trading partner with the US Federal Government.
 
Table of Contents
 
1. Report Overview
1.1. Global Drug Delivery Technology Market Overview
1.2. Global Drug Delivery Technologies Market Segmentation
1.3. Why You Should Read This Report
1.4. How This Report Delivers
1.5. Key Questions Answered by This Analytical Report
1.6. Who Is This Report For?
1.7. Methodology
1.8. Frequently Asked Questions (FAQ)
1.9. Associated Visiongain Reports
1.10. About Visiongain
 
2. Drug Delivery Technology: An Introduction
2.1. Drug Delivery Technologies: Strategies to Improve Existing Drugs
2.2. The Global Drug Delivery Technology Market: Methods of Administration
2.2.1. The Biopharmaceutics Classification System and Using Better Tools to Model Drug Absorption
2.2.2. Sustained/Controlled Release Systems
2.2.3. Oral Drug Delivery: Swallowing Drugs to Reach a Target
2.2.4. Pulmonary Delivery: Delivered by Inhalation
2.2.5. Injection as a Route of Drug Delivery
2.2.6. Transdermal Delivery: More Patient-Friendly
2.2.7. Various Transmucosal Delivery Routes for Delivery
2.2.8. Ocular Delivery: Overcoming Unique Barriers
2.3. Regulation in the US
2.3.1. Regulation of Combination Products
2.3.2. FDA Guidelines for Injectors
2.4. Biopharmaceuticals
2.4.1. An Introduction to the Biological Drugs Market
2.4.2. Biologics: A Rising Drugs Market
2.4.3. Biologics with Associated Drug Delivery Technologies
2.4.4. Pegylated Interferons
2.4.5. Stiff Competition in Insulin Market Stimulating Investment in Drug Delivery Technologies
2.4.6. The Main Challenges Facing Biological Drug Delivery
2.5. Market Definition
 
3. Drug Delivery Technologies: Global Market, 2016-2026
3.1. The Global Drug Delivery Technology Market in 2015
3.2. The Global Drug Delivery Technology Market Forecast 2016-2026
3.3. Drug Delivery Technology: Drivers and Restraints 2016-2026
3.4. Biologics: A Driver for Growth in Drug Delivery Technologies
3.4.1. The Global Biological Drugs Market Forecast
3.4.2. Leading Classes of Biological Drugs
3.4.3. Monoclonal Antibodies: Largest Sector in Biologics
3.4.4. Human insulin: Leading the Therapeutic Protein Segment
3.4.5. Interferon Products for the Treatment of Hepatitis
3.5. Vaccines: Meeting the Unmet Needs
3.5.1. The Global Vaccines Market Forecast
 
4. Drug Delivery Technologies: Submarkets 2016-2026
4.1. The Global Drug Delivery Technology Market by Submarkets
4.2. How Will Segmental Market Shares Change to 2026?
4.3. Oral Drug Delivery Technology
4.3.1. Oral Drug Delivery Technology Market Forecast 2016-2026
4.3.2. Trends and Developments
4.3.2.1. Delivering APIs to the Colon
4.3.2.2. Google Investing in Robotic Pill
4.3.3. Oral Drug Delivery Technologies: Drivers and Restraints 2016-2026
4.4. Inhalable Drug Delivery Technology
4.4.1. Inhalable Drug Delivery Technology Market Forecast 2016-2026
4.4.2. Trends and Developments
4.4.2.1. Inhalable Liposomal Antibiotics to Penetrate Biofilms
4.4.2.2. Condensation Aerosol Generated by Heat
4.4.2.3. Is Inhaled Insulin Marketable?
4.4.3. Inhalable Drug Delivery Technologies: Drivers and Restraints 2016-2026
4.5. Injectable/Implantable Delivery Technology
4.5.1. Injectable/Implantable Delivery Technology Market Forecast 2016-2026
4.5.2. Trends and Developments
4.5.2.1. Ultrasound Activated Targeted Drug Delivery
4.5.2.2. Intradermal Vaccine Delivery
4.5.2.3. First Flu Vaccine Jet Injector Approved in the US
4.5.3. Injectable/Implantable Delivery Technologies: Drivers and Restraints 2016-2026
4.6. Transdermal Drug Delivery Technology
4.6.1. Transdermal Drug Delivery Technology Market Forecast 2016-2026
4.6.2. Trends and Developments
4.6.2.1. Iontophoretic Transdermal Patch for Migraine Approved in the US
4.6.2.2. Microneedle Patch for Vaccine Delivery
4.6.2.3. Ultrasonic Waveforms to Enlarge Skin Pores
4.7. Ocular Drug Delivery Technology
4.7.1. Ocular Drug Delivery Technology Market Forecast 2016-2026
4.7.2. Trends and Developments
4.7.2.1. Non-Surgical Microinjection to Retina and Choroid to be used for Gene Therapy
4.8. Nasal/Buccal Drug Delivery Technology
4.8.1. Nasal/Buccal Drug Delivery Technology Market Forecast 2015-2026
4.8.2. Trends and Developments
4.8.2.1. Nasal Spray with Live Attenuated Influenza Vaccine
4.8.2.2. Mucosal Vaccine Delivered through the Nose or Mouth
4.8.2.3. Buccal Insulin Spray in Clinical Trials
 
5. Drug Delivery Technologies: Leading National Markets, 2016-2026
5.1. Global Drug Delivery Technology Market: Regional Forecast 2016-2026
5.1.1. How Will Regional Market Shares Change to 2026?
5.2. US Drug Delivery Technology Market 2016-2026
5.2.1. US Drug Delivery Technology Market Forecast 2016-2026
5.2.2. Eli Lilly to Establish Drug Delivery Centre
5.3. EU5. Drug Delivery Technology Market 2016-2026
5.3.1. EU5. Drug Delivery Technology Market Forecast 2016-2026
5.3.2. EU5. Drug Delivery Technologies Market: CAGR (%) by Country, 2016-2026
5.3.3. EU5. Markets: Changing Market Shares by Country, 2016-2026
5.3.4. The German Drug Delivery Technology Market Forecast 2016-2026
5.3.5. The French Drug Delivery Technology Market Forecast 2016-2026
5.3.6. The UK Drug Delivery Technology Market Forecast 2016-2026
5.3.7. The Spanish Drug Delivery Technology Market Forecast 2016-2026
5.3.8. The Italian Drug Delivery Technology Market Forecast 2016-2026
5.4. Japanese Drug Delivery Technology Market 2016-2026
5.4.1. Japanese Drug Delivery Technology Market Forecast 2016-2026
5.4.2. The New Sakigake Designation System May Accelerate Innovative Drug Development
5.5. Chinese Drug Delivery Technology Market 2016-2026
5.5.1. Chinese Drug Delivery Technology Market Forecast 2016-2026
5.6. Indian Drug Delivery Technology Market 2016-2026
5.6.1. Indian Drug Delivery Technology Market Forecast 2016-2026
5.7. Brazilian Drug Delivery Technology Market 2016-2026
5.7.1. Brazilian Drug Delivery Technology Market Forecast 2016-2026
5.8. Russian Drug Delivery Technology Market 2016-2026
5.8.1. Russian Drug Delivery Technology Market Forecast 2016-2026
5.9. South Korean Drug Delivery Technology Market 2016-2026
5.9.1. South Korean Drug Delivery Technology Market Forecast 2016-2026
5.10. Mexican Drug Delivery Technology Market 2016-2026
5.10.1. Mexican Drug Delivery Technology Market Forecast 2016-2026
5.11. Rest of the World Drug Delivery Technology Market Forecast 2016-2026
 
6. Leading Companies in the Drug Delivery Technology Market, 2016-2026
6.1. Alkermes: Focused on Extended and Controlled Release
6.1.1. Alkermes: Drug Delivery Technology Portfolio
6.1.2. Long-Acting Injectables
6.1.3. Aristada vs. Abilify Maintena
6.1.4. Oral Controlled Release
6.1.4.1. Nanoparticle Technologies
6.1.5. Other Technologies
6.1.6. Alkermes: Product Portfolio
6.1.7. Alkermes: Pipeline Products 2016
6.1.8. Alkermes Recent Developments
6.1.8.1. Merger with Elan Drug Technologies
6.1.8.2. Alkermes: Future Outlook
6.1.9. Manufacturing Facility in Georgia Sold to Recro Pharma
6.2. 3M: 50. Years of Drug Delivery Technology Development
6.2.1. 3M: Drug Delivery Technology Portfolio
6.2.1.1. Oral and Topical Drug Delivery
6.2.1.2. MDI for Nasal and Inhalable Drugs
6.2.1.3. Transdermal patch Technology
6.2.1.4. Microneedle Technology
6.2.2. 3M: Market Outlook
6.3. Skyepharma: Solutions for Inhalable, Oral, Topical and Injectable Drugs
6.3.1. Skyepharma: Drug Delivery Technology Portfolio
6.3.1.1. Inhalation Drug Delivery Technology
6.3.1.2. Oral Drug Delivery Technology
6.3.1.3. Injectable Drug Delivery Technology
6.3.1.4. Topical Drug Delivery Technology
6.3.2. Skyepharma: Pipeline Products 2016
6.3.3. Skyepharma: Market Outlook
6.4. Becton Dickinson and Company (BD): A History of Hypodermic Needles and Syringes
6.4.1. BD: Drug Delivery Technology Portfolio
6.4.1.1. Prefillable Syringe Systems
6.4.1.2. Self-Injection Systems
6.4.1.3. Pen Needles
6.4.1.4. Safety & Shielding Systems
6.4.2. BD: Future Outlook
6.4.3. New Infusion Set with BD FlowSmart Technology Cleared by FDA
6.4.4. BD Acquired Injection Safety Firms
6.5. Antares Pharma: Leading the Needle-Free Injector Market
6.5.1. Antares Pharma: Drug Delivery Product Portfolio
6.5.2. Antares Pharma: Future Outlook
6.5.3. Antares Pharma: Products in Development
6.6. pSivida: Targeting the Back of the Eye
6.6.1. pSivida: Drug Delivery Technology Portfolio
6.6.1.1. Durasert Technology
6.6.1.2. Tethadur Technology
6.6.2. pSivida: Pipeline Products 2016
6.6.3. pSidiva: Collaborations
6.6.4. pSivida: Future Outlook
6.7. Applied Pharma Research (APR)
6.7.1. APR's Technology and Product Offerings
6.8. Ethypharm
6.8.1. Ethypharm's Currently Marketed Products
6.9. Glycologic
6.9.1. Glycologic's Drug Delivery Technologies
6.9.2. Glycologic's Pipeline Developments
6.10. NanoPass Technologies
6.10.1. NanoPass Drug Delivery Products
6.10.1.1. Anti-aging Microdermabrasion
6.10.1.2. MicronJet Needle
 
7. Qualitative Analysis of the Drug Delivery Technology Market, 2016-2026
7.1. SWOT Analysis of the Drug Delivery Technology Market
7.2. Strengths
7.2.1. Increasing Competition and Patent Expiry in the Biologics Market
7.2.2. The Rise of Biosimilars
7.2.3. Increasing Global Diabetic Population
7.3. Weaknesses
7.3.1. Risk-Conscious Regulatory Bodies Will Make Approval Difficult
7.3.2. Companies Need to Develop a More Liberal Mindset
7.4. Opportunities
7.4.1. Nanotechnology: Innovations That Will Benefit Drug Delivery
7.4.2. Possible New Delivery Methods for Insulin
7.5. Threats
7.5.1. Increasing Specificity of Drug Development Poses Challenges to Speciality Drug Delivery Companies
7.5.2. Cost Effective Solutions May Not Be Available
 
8. Expert Opinions from Our Primary Research
8.1. Mr. Patrice Lewko, Vice President - Global Marketing & Innovation, Nemera
8.1.1. The Current state of the Drug Delivery Technologies Market
8.1.2. Key Pointers to Entering the Drug Delivery Technologies Market
8.1.3. The Key to Success for Novelia
8.1.4. Regions of Interest for Nemera and Prospects for Future Growth
8.1.5. Prospects for New Technologies
8.1.6. Major Challenges and Opportunities
8.2. Mr. Armand Amin, Manager - Systems Development, BioDuro
8.2.1. BioDuro Drug Delivery Technology Solutions
8.2.2. The Importance of Timing
8.2.3. The Current State of the Drug Delivery Technologies Market
8.2.4. Entering the Drug Delivery Technologies Market
8.2.5. New Technologies to Enter the Market
8.2.6. Future Challenges and Opportunities for Drug Delivery Technologies
8.2.7. Opportunities for Growth
 
9. Conclusions
9.1. The Global Drug Delivery Technologies Market in 2015
9.1.1. Current Leading Drug Delivery Technology Segments
9.1.2. Notable Drug Delivery Technology Companies
9.1.3. Leading Regional/National Markets
9.2. Global Drug Delivery Technology Market Forecast 2016-2026
9.3. The Future of the Drug Delivery Technology Market
9.3.1. Transdermal and Injectable Drug Delivery Technologies Set For High Growth
9.3.2. Biologics and Biosimilars to Drive Market Growth
 
10. Glossary
 
Appendix
Visiongain's Bespoke Research Service
Some Associated Reports
Visiongain Report Sales Order Form
About Visiongain
Report Evaluation Form
 
List of Tables
Table 1.1: Global Drug Delivery Technologies Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Region, 2015-2026 (Redacted Data)
Table 2.1: The Biopharmaceutics Classification System, Classification and Description
Table 2.2: Top 5 Biologics by Sales ($bn), 2015
Table 3.1: The Global Drug Delivery Technology Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 3.2: Global Biological Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 3.3: Global Vaccines Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 4.1: The Global Drug Delivery Technology Market by Submarkets: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 4.2: Leading Drug Delivery Market Segments: CAGR (%), 2015-2020, 2020-2026 and 2015-2026
Table 4.3: Leading Drug Delivery Market Segments: Market Share (%), 2015
Table 4.4: Oral Drug Delivery Technology Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 4.5: Inhalable Drug Delivery Technology Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 4.6: Insulin Inhalers Withdrawal from the Market or Pipeline, 2016
Table 4.7: Injectable/Implantable Drug Delivery Technology Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 4.8: Transdermal Drug Delivery Technology Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 4.9: Ocular Drug Delivery Technology Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 4.10: Nasal/Buccal Drug Delivery Technology Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 5.1: The Global Drug Delivery Technologies Market by Country/Region: Revenue ($bn) and Market Share (%), 2015
Table 5.2: Global Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Country/Region, 2015-2026
Table 5.3: Global Drug Delivery Technology Market: Revenue ($bn) by Country/Region, 2015, 2020 and 2026
Table 5.4: Global Drug Delivery Technology Market: Revenue ($bn) and Market Share (%) by Country/Region, 2015
Table 5.5: US Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 5.6: EU5 Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 5.7: EU5 Drug Delivery Technology Market: CAGR (%) by Country, 2015-2020, 2020-2026 and 2015-2026
Table 5.8: EU5 Drug Delivery Technology Market: Market Size ($bn) and Market Share (%) by Country, 2015, 2020 and 2026
Table 5.9: German Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 5.10: French Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 5.11: UK Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 5.12: Spanish Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 5.13: Italian Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 5.14: Japanese Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 5.15: Chinese Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 5.16: Indian Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 5.17: Brazilian Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
Table 5.18: Russian Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 5.19: South Korean Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 5.20: Mexican Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 5.21: Rest of the World Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 6.1: Leading Companies: Areas of Interest by Type of Delivery
Table 6.2: Alkermes: Overview, 2016
Table 6.3: Alkermes: Drug Delivery Technology Portfolio and Pipeline 2016
Table 6.4: Products Utilising Alkermes' Drug Delivery Technology (Indication, Partner and Territory) 2016
Table 6.5: Alkermes: Pipeline Products (Product Candidate, Target Indication and Status), 2016
Table 6.6: Alkermes: Historical Revenue ($m), AGR (%) and CAGR (%), 2010-2015
Table 6.7: Alkermes: Historical Revenue ($m) by Business Segment, 2010-2015
Table 6.8: Alkermes: Manufacturing and Royalty Revenue ($m) by Product, 2014 and 2015
Table 6.9: Alkermes: Revenue ($m) by Main Customers 2014
Table 6.10: 3M: Overview, 2016
Table 6.11: 3M: Health Care Historical Revenue ($bn), AGR (%) and CAGR (%), 2010-2015
Table 6.12: Skyepharma: Overview, 2015
Table 6.13: Skyepharma: Inhalation Drug Formulation Technology Portfolio 2016
Table 6.14: Products Utilising Skyepharma's Inhalation Drug Delivery Technology (Product Name, Indication, Licensee and Description), 2015
Table 6.15: Skyepharma: Oral Drug Formulation Technology Portfolio (Technology, Description and Product Name) 2016
Table 6.16: Products Utilising Skyepharma's Oral Drug Delivery Technology (Product Name, Indication, Licensee and Description), 2016
Table 6.17: Skyepharma: Pipeline Products 2016 (Product Name, Formulation, Region, Indication, Partner Name and Status)
Table 6.18: Skyepharma: Historical Revenue ($m), AGR (%) and CAGR (%), 2010-2015
Table 6.19: Skyepharma: Historical Revenue ($m) by Income Stream, 2010-2015
Table 6.20: BD: Overview, 2016
Table 6.21: BD: Drug Delivery Products by Segment, 2016
Table 6.22: BD: Historical Revenue ($bn) by Geographic Region, 2012-2015
Table 6.23: BD Medical: Historical Revenue ($bn), AGR (%) and CAGR (%), 2010-2015
Table 6.24: Antares Pharma: Overview, 2016
Table 6.25: Antares Pharma: Product Portfolio (Product, Drug, Partner, Indication and Territory
Table 6.26: Antares Revenue from Major Customers: Revenue ($m) and Revenue Share (%), 2014 and 2015
Table 6.27: Antares Revenue by Region: Revenue ($m) and Revenue Share (%), 2014 and 2015
Table 6.28: Antares Pharma: Historical Revenue ($m), AGR (%) and CAGR (%), 2010-2015
Table 6.29: Antares Pharma: Products in Development 2016 (Product Name, Drug, Partner, Indication, Territory and Regulatory Status)
Table 6.30: pSivida: Overview, 2015
Table 6.31: Products Utilising Durasert Technology 2015 (Product, Indication, Status and Partner)
Table 6.32: pSivida: Historical Revenue ($m), AGR (%) and CAGR (%), 2010-2015
Table 6.33: pSivida: Historical Revenue ($m) by Income Stream, 2010-2015
Table 6.34: Selected Ethypharm's Pain Relieving Products, 2015
Table 7.1: SWOT Analysis of the Drug Delivery Technology Market, 2016-2026
 
List of Figures
Figure 3.1: The Global Drug Delivery Technology Market: Revenue ($bn) and AGR (%), 2015-2026
Figure 3.2: Drug Delivery Technologies: Market Drivers and Restraints 2016-2026
Figure 3.3: Global Biological Drugs Market: Revenue ($bn) and AGR (%), 2015-2026
Figure 3.4: Global Vaccines Market: Revenues ($bn) and AGR (%), 2015-2026
Figure 4.1: Leading Drug Delivery Market Segments: CAGR (%), 2015-2020
Figure 4.2: Leading Drug Delivery Market Segments: CAGR (%), 2020-2026
Figure 4.3: Leading Drug Delivery Market Segments: CAGR (%), 2015-2026
Figure 4.4: Market Shares (%) of Leading Drug Delivery Market Segments, 2015
Figure 4.5: Market Shares (%) of Leading Drug Delivery Market Segments, 2020
Figure 4.6: Market Shares (%) of Leading Drug Delivery Market Segments, 2026
Figure 4.7: Oral Drug Delivery Technology Market: Revenue ($bn) and AGR (%), 2015-2026
Figure 4.8: Oral Drug Delivery Technologies: Drivers and Restraints 2016-2026
Figure 4.9: Inhalable Drug Delivery Technology Market: Revenue ($bn) and AGR (%), 2015-2026
Figure 4.10: Inhalable Drug Delivery Technologies: Drivers and Restraints 2016-2026
Figure 4.11: Injectable/Implantable Drug Delivery Technology Market: Revenue ($bn) and AGR (%), 2015-2026
Figure 4.12: Injectable/implantable Drug Delivery Technologies: Drivers and Restraints 2015-2026
Figure 4.13: Transdermal Drug Delivery Technology Market: Revenue ($bn) and AGR (%), 2015-2026
Figure 4.14: Ocular Drug Delivery Technology Market: Revenue ($bn) and AGR (%), 2015-2026
Figure 4.15: Nasal/Buccal Drug Delivery Technology Market: Revenue ($bn) and AGR (%), 2015-2026
Figure 5.1: The Global Drug Delivery Technologies Market by Country/Region: Revenue ($bn), 2015
Figure 5.2: Global Drug Delivery Technology Market: Revenue ($bn) by Country/Region, 2015, 2020 and 2026
Figure 5.3: Global Drug Delivery Technology Market: CAGR (%) by Country/Region, 2015-2020
Figure 5.4: Global Drug Delivery Technology Market: CAGR (%) by Country/Region, 2020-2026
Figure 5.5: Global Drug Delivery Technology Market: CAGR (%) by Country/Region 2015-2026
Figure 5.6: Global Drug Delivery Technology Market: Market Share (%) by Country/Region, 2015
Figure 5.7: Global Drug Delivery Technology Market: Market Share (%) by Country/Region, 2020
Figure 5.8: Global Drug Delivery Technology Market: Market Share (%) by Country/Region, 2026
Figure 5.9: US Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 5.10: EU5 Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 5.11: EU5 Drug Delivery Technology Market: CAGR (%) by Country, 2015-2020
Figure 5.12: EU5 Drug Delivery Technology Market: by Country, 2020-2026
Figure 5.13: EU5 Drug Delivery Technology Market: CAGR (%) by Country, 2015-2026
Figure 5.14: EU5 Drug Delivery Technology Market: Market Share (%) by Country, 2015
Figure 5.15: EU5 Drug Delivery Technology Market: Market Share (%) by Country, 2020
Figure 5.16: EU5 Drug Delivery Technology Market: Market Share (%) by Country, 2026
Figure 5.17: German Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 5.18: French Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 5.19: UK Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 5.20: Spanish Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 5.21: Italian Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 5.22: Japanese Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 5.23: Chinese Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 5.24: Indian Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 5.25: Brazilian Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 5.26: Russian Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 5.27: South Korean Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 5.28: Mexican Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 5.29: Rest of the World Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 6.1: Alkermes: Historical Revenue ($m) and AGR (%), 2010-2015
Figure 6.2: Alkermes Historical Revenue ($m): Manufacturing and Royalty Turnover, and Net Product Sales, 2010-2015
Figure 6.3: Alkermes: Manufacturing and Royalty Revenue ($m) by Product, 2014 and 2015
Figure 6.4: Alkermes: Revenue Share (%) by Main Customers 2014
Figure 6.5: Alkermes: Revenue Share (%) by Main Customers 2015
Figure 6.6: 3M: Health Care Historical Revenue ($bn) and AGR (%), 2010-2015
Figure 6.7: Skyepharma: Historical Revenue ($m) and AGR (%), 2010-2015
Figure 6.8: Skyepharma: Historical Revenue ($m) by Income Stream, 2010-2015
Figure 6.9: BD: Historical Revenue ($bn) by Geographic Region, 2012-2015
Figure 6.10: BD Medical: Historical Revenue ($bn) and AGR (%), 2010-2015
Figure 6.11: Antares Revenue from Major Customers: Revenue Share (%), 2014
Figure 6.12: Antares Revenue from Major Customers: Revenue Share (%), 2015
Figure 6.13: Antares Revenue by Region: Revenue Share (%), 2014
Figure 6.14: Antares Revenue by Region: Revenue Share (%), 2015
Figure 6.15: Antares Pharma: Historical Revenue ($m) and AGR (%), 2010-2015
Figure 6.16: pSivida: Historical Revenue ($m) and AGR (%), 2010-2015
Figure 6.17: pSivida: Historical Revenue ($m) by Income Stream, 2010-2015
 
Companies Listed
3M
Acorda
Actavis
Adamis
Aleza Pharmaceuticals
Alkermes
Almirall
Alza
Antares Pharma
Applied Pharma Research
Aradigm
Astellas
AstraZeneca
Bayer HealthCare Pharmaceuticals
BD
Biogen
BioGeneration Ventures
Bioject Medical Technologies
Boehringer Ingelheim
Bristol Myers Squibb
CareFusion Corporation
Cephalon
Changchun BCHT
Chiesi
Chrono Therapeutics
Cilag
Cima Labs
Clearside
Cosmo Pharmaceuticals
CRISI Medical Systems
CTCBIO
Daiichi
Elan Drug Technologies
Elcam Medical
Eli Lilly
Ethypharm
Ferrer
Ferring
Flamel
Genentech
GlaxoSmithKline
Glycologic
Google
GSK
Haselmeir
Horizon Pharma
ImmusanT
Innovent Biologics
Insmed
Invion
iScience Interventional Corporation
J&J
Janssen
JCR Pharmaceuticals
Kyorin
MannKind
Meda Pharmaceuticals
Medac
Medimetrics
MedImmune
MedSciences Capital
Merck Serono
Mucosis
Mundipharma
Nanopass Technologies
Nektar Therapeutics
Nexvax2
NHTherapeutics
Novartis
Novo Nordisk
NuPathe
NV NOM
Oramed
OwenMumford
Pacira Pharmaceuticals
Pari Pharma
Permatec
Pfizer
PharmaJet
Presspart
ProStrakan
pSivida
Pulmagen
Ranbaxy
Rani Therapeutics
Recro Pharma
Regeneron Pharmaceuticals
Roche
Sandoz
Sanofi-Aventis
Santen
Shionogi
SHL Group
Shreya Life Sciences
Skyepharma
Smoofi
Spark Therapeutics
STADA Arzneimittel
Takeda
Teva
UU Holdings
Vetter Pharma
West Pharmaceuticals
Ypsomed
 
Organisations Mentioned in the Report
Emory University School of Medicine
Georgia Institute of Technology
Hospital for Special Surgery
University of Oxford

关于我们|联系我们|常见问题|服务项目|购买流程
2005-2013 All rights reserved.京ICP备05069564号-4 京公网安备110108 02010359号
全国服务热线:400-009-0050北京:010-82863481上海:021-64871266

在线客服系统